Login
Search
Search
0 Dates
2026
2025
2024
2023
2022
2021
2020
2019
2018
0 Events
CPC 2018
CPC 2019
Curso de Atualização em Medicina Cardiovascular 2019
Reunião Anual Conjunta dos Grupos de Estudo de Cirurgia Cardíaca, Doenças Valvulares e Ecocardiografia da SPC
CPC 2020
CPC 2021
CPC 2022
CPC 2023
CPC 2024
CPC 2025
CPC 2026
0 Topics
A. Basics
B. Imaging
C. Arrhythmias and Device Therapy
D. Heart Failure
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
G. Aortic Disease, Peripheral Vascular Disease, Stroke
H. Interventional Cardiology and Cardiovascular Surgery
I. Hypertension
J. Preventive Cardiology
K. Cardiovascular Disease In Special Populations
L. Cardiovascular Pharmacology
M. Cardiovascular Nursing
N. E-Cardiology / Digital Health, Public Health, Health Economics, Research Methodology
O. Basic Science
P. Other
0 Themes
01. History of Cardiology
02. Clinical Skills
03. Imaging
04. Arrhythmias, General
05. Atrial Fibrillation
06. Supraventricular Tachycardia (non-AF)
07. Syncope and Bradycardia
08. Ventricular Arrhythmias and Sudden Cardiac Death (SCD)
09. Device Therapy
10. Chronic Heart Failure
11. Acute Heart Failure
12. Coronary Artery Disease (Chronic)
13. Acute Coronary Syndromes
14. Acute Cardiac Care
15. Valvular Heart Disease
16. Infective Endocarditis
17. Myocardial Disease
18. Pericardial Disease
19. Tumors of the Heart
20. Congenital Heart Disease and Pediatric Cardiology
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
22. Aortic Disease
23. Peripheral Vascular and Cerebrovascular Disease
24. Stroke
25. Interventional Cardiology
26. Cardiovascular Surgery
27. Hypertension
28. Risk Factors and Prevention
29. Rehabilitation and Sports Cardiology
30. Cardiovascular Disease in Special Populations
31. Pharmacology and Pharmacotherapy
32. Cardiovascular Nursing
33. e-Cardiology / Digital Health
34. Public Health and Health Economics
35. Research Methodology
36. Basic Science
37. Miscellanea
0 Resources
Abstract
Slides
Vídeo
Report
CLEAR FILTERS
Epidemiology and Outcomes of Driveline Infections in HeartMate 3 Recipients
Session:
Sessão de Posters 50 - Terapêuticas avançadas na insuficiência cardíaca e em populações especiais
Speaker:
Inês Coutinho Dos Santos
Congress:
CPC 2026
Topic:
D. Heart Failure
Theme:
10. Chronic Heart Failure
Subtheme:
10.2 Chronic Heart Failure – Epidemiology, Prognosis, Outcome
Session Type:
Posters Eletrónicos
FP Number:
---
Authors:
Inês Coutinho dos Santos; Samuel Azevedo; Cátia Sampaio; André Garcia Moniz; Márcia Presume; Ana Rita Bello; Sérgio Maltês; Bruno Rocha; Catarina Brízido; Christopher Strong; Marta Marques; Carlos Aguiar
Abstract
<p style="text-align:justify"><strong>Introduction</strong>: Durable left ventricular assist device (LVAD) therapy has significantly improved survival and quality of life of advanced heart failure (AHF) patients. However, device-related complications such as driveline infections (DLI) remain a critical clinical challenge.</p> <p style="text-align:justify"><strong>Objectives</strong>: To describe the epidemiology, microbiology, management strategies, and outcomes of driveline-related infections experienced by patients under LVAD with HeartMate 3™ (HM3).</p> <p style="text-align:justify"><strong>Methods</strong>: Retrospective observational study including all patients implanted a HM3 between 2018 and 2025 and/or under HM3 follow-up at a single tertiary center. Patients on HM3 support for less than three months were excluded. Clinical data regarding DLI events, their management strategy and outcomes was collected. Descriptive statistics were performed.</p> <p style="text-align:justify"><strong>Results</strong>: Twenty-four HM3 recipients were included (mean age 55.1 ± 11.3 years, 87.5% male), most implanted in a bridge-to-transplantation strategy (45.8%), and most with previous ischemic cardiomyopathy (58.3%). Recurrent non-compliance with driveline care instructions was observed in 25% of patients. Overall, 50% of HM3 recipients registered at least one DLI episode, with a total of 29 suspected DLI episodes during a mean follow-up of 31.1 ± 21.0 months and a median HM3 support duration of 19.0 months. Driveline exudate cultures were positive in 79.3% of cases. Gram-positive bacteria predominated, namely Staphylococcus aureus. Beta-lactams were the most frequently used antibiotics (AB), specifically oral flucloxacillin and i.v. piperacillin-tazobactam. Median AB duration was of 14 days. Associated bacteremia was only found in three cases and two patients were treated for HM3-related endocarditis. Chronic colonization was assumed in four cases. Long-term suppressive AB was needed in five cases. Hospitalization for DLI management was required in 48.3%. Invasive interventions, such as surgical debridement and driveline revision, occurred in five cases. There was one case of DLI-related death due to septic shock, and two urgent heart transplantation listings due to recurrent or refractory DLI.</p> <p style="text-align:justify"><strong>Conclusion</strong>: In this HM3 cohort, DLI represented significant clinical burden, often requiring hospitalization and prolonged AB therapy. However, severe infections were relatively uncommon and invasive procedures were only needed in very select cases. These findings underline the need for optimized patient education and preventive strategies to reduce morbidity and improve long-term outcomes in HM3 recipients.</p>
Our mission: To reduce the burden of cardiovascular disease
Visit our site